Barclays Initiates Coverage On TransMedics Group with Overweight Rating, Announces Price Target of $120
Benzinga Newsdesk 3 weeks ago
Analyst RatingsNewsInitiationPrice Target
Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.
Barclays analyst Christopher Pasquale initiates coverage on TransMedics Group (NASDAQ:TMDX) with a Overweight rating and announces Price Target of $120.